This Study Aims to Find the Best Dose of BI 907828 in Patients With Different Types of Advanced Cancer (Solid Tumors)
Study Details
Study Description
Brief Summary
This study is open to adults with different types of advanced cancer (solid tumors). The purpose of this study is to find out the most suitable dose of BI 907828 the participants can tolerate. The most suitable dose is used in the second part to find out whether BI 907828 makes tumors shrink.
In this study, BI 907828 is given to humans for the first time. BI 907828 is a so-called MDM2 inhibitor that is being developed to treat cancer. BI 907828 is taken as a tablet. Participants either take a dose of BI 907828 on one day every 3 weeks or on two days every 4 weeks.
The participants are in the study for as long as they benefit from and can tolerate treatment. The doctors regularly check the participants' general health during the study.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Dose Escalation
|
Drug: BI 907828
Film-coated tablet
|
| Experimental: Dose Expansion
|
Drug: BI 907828
Film-coated tablet
|
Outcome Measures
Primary Outcome Measures
- Phase Ia- Maximum tolerated dose (MTD) based on number of patients with dose limiting toxicities (DLTs) during first treatment cycle [Up to 28 days]
- Phase Ib - Progression-free survival [Up to 24 months]
- Phase Ia - Number of patients with DLTs during first treatment cycle (21 days, Arm A; 28 days, Arm B) [Up to 28 days]
- Phase Ib - Number of patients with DLTs during the first treatment cycle [Up to 28 days]
Secondary Outcome Measures
- Phase Ia - Cmax: Maximum measured concentration of BI 907828 in plasma [Up to 24 months]
- Phase Ia - AUC0-∞: Area under the concentration-time curve in plasma over the time interval from 0 extrapolated to infinity [Up to 24 months]
- Phase Ib - Objective response [Up to 24 months]
- Phase Ib - Overall survival [Up to 24 months]
- Phase Ib - Number of patients with Grade ≥3 treatment-related adverse events observed during the entire treatment period [Up to 24 months]
- Phase Ib - Cmax: Maximum measured concentration of BI 907828 in plasma [Up to 24 months]
- Phase Ib - AUC0-∞: Area under the concentration-time curve in plasma over the time interval from 0 extrapolated to infinity [Up to 24 months]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Provision of signed and dated, written informed consent form ICF in accordance with ICH-GCP and local legislation prior to any trial-specific procedures, sampling, or analyses.
-
Pathologically documented, advanced solid tumors.
-
Patients fulfilling one or more of the following criteria:
-
Radiologically documented disease progression or relapse
-
Patients who are not eligible to receive standard of care treatments, and for whom no proven treatments exist.
-
Patients with MDM2 amplified sarcomas who require first line treatment (for Ph Ib/dose expansion - Cohort 1 only).
-
Patients with MDM2 amplified sarcomas may fulfil any one of the above three criteria to be considered eligible.
-
Phase Ia (dose escalation) only:
-
Patient has a tumor with either a known TP53 wild type status, or unknown TP53 status, and regardless of MDM2 amplification status, at the time of study entry.
-
Phase Ib (expansion phase) only:
-
Cohort 1: TP53 wt and MDM2-amplified sarcoma with advanced/metastatic disease at any line of therapy. If TP53 status is not available during screening, the patient may be included with unknown TP53 status if a tissue sample is submitted for central laboratory assessment. If TP53 status cannot be evaluated, the patient may be included if agreed between the Investigator and Sponsor.
-
Cohort 2: TP53 wt and MDM2- amplified NSCLC, urothelial, gastric, biliary tract (including cholangiocarcinoma, intra- and extrahepatic biliary tree, gall blander and ampulla of vater) or pancreatic solidPDAC tumors who have had at least one previous line of therapy for advanced/metastatic disease. If TP53 status cannot be evaluated the patient may be included if agreed between the Investigator and Sponsor
-
Phase Ia (dose escalation) only:
-
Patient with either measurable or non-measurable disease.
-
Non-evaluable disease allowed.
-
Phase Ib (expansion phase) only:
-
At least one target lesion that can be accurately measured per RECIST v.1.1.
-
Phase Ia:
-
Patient must be willing to undergo blood sampling for PK, pharmacodynamic, biomarker, and PGx analyses.
-
Phase Ib:
-
Patient must be willing to undergo tumor biopsy sampling for pharmacodynamic analyses and blood sampling for PK, pharmacodynamics, and biomarker analyses.
-
Willingness to provide a fresh tumor tissue sample obtained after relapse/ progression during or after prior therapy. In case a fresh biopsy cannot be obtained (e.g. inaccessible lesions or patient safety concern), an archived specimen, collected before screening within 12 months of enrollment, may be submitted. If these requirements cannot be met, then the patient may be allowed to enter the study at Sponsor discretion, after agreement between the Investigator and Sponsor.
-
Further inclusion criteria apply
Exclusion Criteria:
-
Previous administration of BI 907828 or any other MDM2-p53 or MDMX (MDM4)-p53 antagonist.
-
Known TP53 mutant tumor.
-
Symptomatic metastases from non-brain tumors. Note: Patients with previously treated brain metastases may participate provided they are stable, without evidence of progression by imaging (using the identical imaging modality for each assessment, either MRI or computed tomography (CT) scan), for at least four weeks prior to the first dose of trial treatment, and any neurologic symptoms have returned to baseline; have no evidence of new or enlarging brain metastases. Patients on corticosteroids must have a stable dose for at least 5 days prior to baseline MRI.
-
Patients with history of bleeding diathesis.
-
Major surgery (major according to the Investigator's assessment) performed within 12 weeks prior to start of study treatment, or planned within 12 months after screening (e.g. hip replacement).
-
Any other documented active or suspected malignancy or history of malignancy within 3 years prior to screening, except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of uterine cervix, or other local tumors considered cured by local treatment.
-
Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial.
-
Further exclusion criteria apply.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Yale University School of Medicine | New Haven | Connecticut | United States | 06511 |
| 2 | Florida Cancer Specialists | Sarasota | Florida | United States | 34232 |
| 3 | Memorial Sloan-Kettering Cancer Center | New York | New York | United States | 10065 |
| 4 | Tennessee Oncology, PLLC | Nashville | Tennessee | United States | 37203 |
| 5 | UZ Leuven | Leuven | Belgium | 3000 | |
| 6 | The Ottawa Hospital | Ottawa | Ontario | Canada | K1H 8L6 |
| 7 | Helios Klinikum Berlin-Buch | Berlin | Germany | 13125 | |
| 8 | Universitätsklinikum Köln (AöR) | Köln | Germany | 50937 | |
| 9 | Universitätsklinikum Tübingen | Tübingen | Germany | 72076 | |
| 10 | National Cancer Center Hospital | Tokyo, Chuo-ku | Japan | 104-0045 | |
| 11 | MED POLONIA SP Z O O, Clinical Trials Department,Poznan | Poznan | Poland | 60-693 | |
| 12 | Oncology Center-Maria Sklodowska-Curie Institute | Warsaw | Poland | 02-034 | |
| 13 | Hospital Vall d'Hebron | Barcelona | Spain | 08035 | |
| 14 | Hospital Clínic de Barcelona | Barcelona | Spain | 08036 |
Sponsors and Collaborators
- Boehringer Ingelheim
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- 1403-0001
- 2017-003210-95